Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma...
The policy of reimbursing multigene testing and pembrolizumab produced patient survival improvements, but selectivity of response prevented population mortality improvement. Health-care system costs...
pubmed.ncbi.nlm.nih.gov